je.st
news
Tag: statement
Statement T-shirts allow kids to send a message without taking a fashion risk
2013-08-08 22:48:09| Apparel - Topix.net
The T-shirt is one of fashion's most basic items, but even with today's popular slim cuts, there's wiggle room to change up the style.
Tags: send
message
statement
taking
PG&E Introduces New Energy Statement To Help Customers Better Understand And Manage Energy Use
2013-08-07 22:38:00| Transmission & Distribution World
Starting Aug. 2, PG&E's 6.2 million customers will receive an all-new energy statement for electric and gas services, featuring a larger type size, at-a-glance billing numbers, and new information that will help them better understand and manage their energy usage. read more
Tags: use
statement
energy
understand
View Preliminary Official Statement
2013-08-02 16:33:17| PortlandOnline
HTML Document, 27kbCategory: Current Offerings
Tags: view
statement
official
preliminary
MSD Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 16:16:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Sharpe and Dohme (MSD), known as Merck in the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MSDMedia:Pam Eisele, +1-908-423-5042Michael Close, +1-267-305-1211Investor:Carol Ferguson, +1-908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 15:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
Sites : [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] next »